| | The coronavirus |
| |
The number of people infected by the coronavirus in Tokyo may have increased nine-fold since last summer, antibody tests showed, as Japan tries to rein in the country’s third and most lethal wave of the pandemic ahead of the Olympics in July.
Pfizer said it had withdrawn an application for emergency-use authorization of its vaccine in India, after failing to meet the drug regulator’s demand for a local safety and immunogenicity study.
Johnson & Johnson said it has asked U.S. health regulators to authorize its single-dose vaccine for emergency use, and it will apply to European authorities in coming weeks.
Australia’s biggest state will exit a snap five-day lockdown after reporting no cases for five straight days, as the national cabinet decided to lift the temporary caps on citizens returning from overseas from the middle of this month.
New Zealand said it will start receiving refugees again this month, nearly a year after it shut its borders to stop the spread of COVID-19. A group of 35 refugees will arrive in February, with about 210 refugees expected to enter the country by June 30, Immigration New Zealand and officials said.
| |
| |
From Breakingviews - Corona Capital: BNP, Beer, Planes, Paint, Debt Bidders agreed on a ceasefire on Signature Aviation; an M&A tussle over a Finnish paint company intensifies. Catch up with today’s Corona Capital. | |
| |
Reuters reporters and editors around the world are investigating the response to the coronavirus pandemic.
We need your help to tell these stories. Our news organization wants to capture the full scope of what’s happening and how we got here by drawing on a wide variety of sources.
Are you a government employee or contractor involved in coronavirus testing or the wider public health response? Are you a doctor, nurse or health worker caring for patients? Have you worked on similar outbreaks in the past? Has the disease known as COVID-19 personally affected you or your family? Are you aware of new problems that are about to emerge, such as critical supply shortages?
We need your tips, firsthand accounts, relevant documents or expert knowledge. Please contact us at coronavirus@reuters.com.
We prefer tips from named sources, but if you’d rather remain anonymous, you can submit a confidential news tip. Here’s how. | |
|
| |